Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.480
-0.020 (-0.44%)
Mar 17, 2026, 2:20 PM EDT - Market open
Coya Therapeutics Revenue
In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth. Coya Therapeutics had revenue of $3.96M in the quarter ending December 31, 2025, with 202,768.80% growth.
Revenue (ttm)
$7.95M
Revenue Growth
+123.57%
P/S Ratio
13.40
Revenue / Employee
$993,219
Employees
8
Market Cap
105.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 62.30M |
| Gossamer Bio | 44.05M |
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 2.82M |
| Inovio Pharmaceuticals | 65.34K |
| Genelux | 8.00K |
COYA News
- 1 day ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - Business Wire
- 5 weeks ago - Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial - Business Wire
- 6 weeks ago - Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
- 2 months ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 2 months ago - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
- 2 months ago - Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - Business Wire
- 3 months ago - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 3 months ago - Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire